Photo of Halina Offner,

Halina Offner

    • Professor of Neurology School of Medicine

Education

  • MSc, University of Lodz, 0 Poland 1969

Publications

  • "Novel feedback loop between M2 macrophages/microglia and regulatory B cells in estrogen-protected EAE mice." Journal of Neuroimmunology  In: , Vol. 305, 15.04.2017, p. 59-67.
  • "DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury." Metabolic Brain Disease  In: , 16.03.2017, p. 1-8.
  • "Sex differences in the immune response to experimental stroke : Implications for translational research." Journal of Neuroscience Research  In: , Vol. 95, No. 1-2, 01.01.2017, p. 437-446.
  • "Stroke and other cerebrovascular diseases." Neurochemistry International In: , 2017.
  • "DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury." Translational Stroke Research  In: , 17.12.2016, p. 1-10.
  • "Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke." Neurochemistry International  In: , 13.09.2016.
  • "Partial MHC class II constructs as novel immunomodulatory therapy for stroke." Neurochemistry International  In: , 01.09.2016.
  • "Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis." Journal of Neuroimmunology  In: , Vol. 293, 15.04.2016, p. 45-53.
  • "Loss of PPARα perpetuates sex differences in stroke reflected by peripheral immune mechanisms." Metabolic Brain Disease  In: , 12.02.2016, p. 1-10.
  • "A novel mouse model of thromboembolic stroke." Journal of Neuroscience Methods In: , Vol. 256, 30.12.2015, p. 203-211.
  • "Role for microglia in sex differences after ischemic stroke : importance of M2." Metabolic Brain Disease  In: , Vol. 30, No. 6, 01.12.2015, p. 1515-1529.
  • "Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion." Translational Stroke Research  In: , 01.12.2015, p. 1-9.
  • "Sex differences and the role of PPAR alpha in experimental stroke." Metabolic Brain Disease  In: , 18.11.2015, p. 1-9.
  • "Treatment with IL-10 producing B cells in combination with E2 ameliorates EAE severity and decreases CNS inflammation in B cell-deficient mice." Metabolic Brain Disease  In: , Vol. 30, No. 5, 10.10.2015, p. 1117-1127.
  • "HLA-DRaα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection." Journal of Neuroinflammation In: , Vol. 12, No. 1, 123, 24.06.2015.
  • "Functional Role of Regulatory Lymphocytes in Stroke." Stroke  In: , Vol. 46, No. 5, 20.05.2015, p. 1422-1430.
  • "Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice." Neuroscience In: , Vol. 288, 02.03.2015, p. 112-119.
  • "The role of the spleen in ischemic stroke." Journal of Cerebral Blood Flow and Metabolism  In: , Vol. 35, No. 2, 02.02.2015, p. 186-187.
  • "Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke." Journal of Neuroimmunology  In: , Vol. 278, 15.01.2015, p. 289-298.
  • "Regulatory CD8CD122 T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells." Metabolic Brain Disease  In: , Vol. 30, No. 4, A003, 2015, p. 911-924.
  • "IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice." Journal of Neuroimmunology  In: , Vol. 285, 2015, p. 129-136.
  • "PD-L1 monoclonal antibody treats ischemic stroke by controlling central nervous system inflammation." Stroke  In: , Vol. 46, No. 10, 2015, p. 2926-2934.
  • "Modeling immunity and inflammation in stroke : don't be afraid of mice?" Stroke  In: , Vol. 45, No. 9, 01.09.2014, p. e181-e182.
  • "HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis." Journal of Immunology In: , Vol. 192, No. 9, 01.05.2014, p. 4164-4173.
  • "Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke." Translational Stroke Research In: , Vol. 5, No. 5, 2014, p. 612-617.
  • "Preclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke." Translational Stroke Research In: , Vol. 6, No. 1, 2014, p. 60-68.
  • "Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis." Metabolic Brain Disease  In: , Vol. 30, No. 1, 2014, p. 57-65.
  • "A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke." Metabolic Brain Disease  In: , Vol. 29, No. 1, 2014, p. 37-45.
  • "Novel Humanized Recombinant T Cell Receptor Ligands Protect the Female Brain After Experimental Stroke." Translational Stroke Research In: , Vol. 5, No. 5, 2014, p. 577-585.
  • "Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy." Frontiers in Cellular Neuroscience  In: , Vol. 8, No. SEP, 2014, p. 1-13.

Additional information

Edit profile